GYROS PATENT AB – Trademark Portfolio
Entity Type: 11
GYROS PATENT AB holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 9 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include GYROS, REXXIP, BIOAFFY, GYROLAB, and GYROPLEX. The owner is based in UPPSALA.
Uppsala Science Park
Dag Hammarskjölds väg 54
UPPSALA 751 83 , SE
Showing of trademarks Trademarks
Trademark Classifications
GYROS PATENT AB's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does GYROS PATENT AB have?
GYROS PATENT AB has 9 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 abandoned.
What trademark classes does GYROS PATENT AB file in?
GYROS PATENT AB files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are GYROS PATENT AB's most well-known trademarks?
GYROS PATENT AB's registered trademark portfolio includes well-known marks such as GYROS, REXXIP, BIOAFFY, GYROLAB, and GYROPLEX. These are among 7 currently registered trademarks in the portfolio.
What is GYROS PATENT AB's trademark registration success rate?
GYROS PATENT AB has a 88% trademark registration rate, with 7 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.